Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VTVT vs CRMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRMD Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

CRMD Overall Winner 6-Pillar Tally: VTVT 2 – 4 CRMD Matrix Metrics: VTVT 2 – 8 CRMD

As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over vTv Therapeutics Inc. (VTVT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VTVT carries a Unified Composite Score of 39.2/100 (SELL) at $17.62 (N/M Forward P/E, -29.8% operating margin), whereas CRMD carries 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin).

  • Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (53.2/100 HOLD vs. VTVT 39.2/100 SELL) and 1.20β · 107% Vol risk profile, whereas VTVT leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VTVT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 19.7); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VTVT vs CRMD
VTVT NASDAQ
vTv Therapeutics Inc. Class A Common Stock
Pharmaceutical Preparations
$17.62
-10.51% 1D
Market Cap $78.3M
TTM Revenue $37M
Forward P/E N/M
Beta / 30D Vol 1.48β · 53% Vol
Unified Composite Score
39.2 / 100 SELL
Tech 25.0 Fund 44.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.4%), weak momentum, RSI 20
RSI-14: 19.7 · SMA20: $23.70 · SMA50: $27.74
CRMD NASDAQ Head-to-Head Winner
CorMedix Inc.
Pharmaceutical Preparations
$4.92
+5.47% 1D
Market Cap $384.7M
TTM Revenue $1.05B
Forward P/E 49.0x
Beta / 30D Vol 1.20β · 107% Vol
Unified Composite Score
53.2 / 100 HOLD
Tech 60.0 Fund 60.0 Flow 69.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.2%), weak momentum, RSI 29
RSI-14: 29.3 · SMA20: $6.32 · SMA50: $7.11

6-Pillar Scorecard Institutional Category Breakdown (VTVT 2 – 4 CRMD)

Columns: Metric · VTVT · CRMD
1. Valuation Multiples CRMD
Forward P/E N/M 49.0x
Trailing P/E N/M 2.4x
PEG Ratio N/M 3.79x
EV / Revenue 2.1x N/M
2. Growth & Scale CRMD
Revenue Growth (YoY) +0.0% -47.7%
Earnings Growth (YoY) +0.0% +6.7%
TTM Revenue (USD) $37M $1.05B
Market Cap $78.3M $384.7M
3. Profitability & Quality CRMD
Gross Margin 51.5% 87.4%
Operating Margin -29.8% 41.0%
Net Profit Margin -20.8% 15.5%
Return on Equity (ROE) -10.9% 15.3%
4. Balance Sheet & Cash Flow CRMD
Cash Generation (TTM) -$11M EBITDA $785M
Cash Flow Margin -29.8% EBITDA Mgn 74.6%
Net Cash / Leverage $5.61 Book/Sh · -10.9% ROE $535M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VTVT
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 56.3% (25th %ile)
Put/Call OI Skew N/A 0.69x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat VTVT
OpEx & R&D Intensity 81.3% of Rev ($30M) 46.4% of Rev ($488M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VTVT (2) vs CRMD (8)
Institutional Metric VTVT CRMD Criterion Row Edge
Market Capitalization
Scale
$78.3M $384.7M Larger Scale CRMD
Trailing P/E Ratio
Valuation
N/M 2.4x Lower Multiple CRMD
Forward P/E Ratio
Valuation
N/M 49.0x Lower Multiple CRMD
Revenue Growth (YoY)
Growth
+0.0% -47.7% Higher Growth VTVT
Operating Margin (TTM)
Profitability
-29.8% 41.0% Higher Margin CRMD
Net Profit Margin
Profitability
-20.8% 15.5% Higher Margin CRMD
Return on Equity (ROE)
Capital Efficiency
-10.9% 15.3% Higher ROE CRMD
52-Week Range Position
Momentum
1% ($17–$44) 3% ($5–$13) Stronger Trend CRMD
Beta / 30D Volatility
Risk Regime
1.48β · 53% Vol 1.20β · 107% Vol Lower Realized Risk VTVT
Unified Institutional Score
Composite Signal
39.2 / 100 (SELL) 53.2 / 100 (HOLD) Higher Composite CRMD
Trailing 12M Revenue (USD)
Operating Scale
$37M $1.05B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
51.5% 87.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.1x EV/Rev 3.79x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($5.61 Book/Sh · -10.9% ROE) $785M ($535M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CRMD +1.31 pp
VTVT: -33.61% · CRMD: -32.3%
3M Horizon CRMD +4.19 pp
VTVT: -44.03% · CRMD: -39.84%
6M Horizon CRMD +12.49 pp
VTVT: -50.35% · CRMD: -37.86%
1Y Horizon VTVT +12.51 pp
VTVT: -43.65% · CRMD: -56.16%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VTVT vs CRMD. Trailing 12-month operating profitability (VTVT -29.8% vs CRMD 41.0%) and valuation multiples (VTVT N/M vs CRMD 49.0x Forward P/E) are benchmarked directly in Pillar 4 below.

VTVT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$37M
Gross Margin51.5%
Op. Margin-29.8%
ROE / Fwd P/E-10.9% · N/M
CRMD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.05B
Gross Margin87.4%
Op. Margin41.0%
ROE / Fwd P/E15.3% · 49.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VTVT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTVT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRMD BREAKDOWN
109d in phase · OBV DISTRIBUTION
Current IV 56.3%
IV Percentile 25th %ile
Put/Call OI Skew 0.69x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VTVT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $78.3M market capitalization and -29.8% operating margin.
OpEx & R&D Reinvestment 81.3% of Rev ($30M)
90D Engineering Disclosures 0 Published
CRMD Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $384.7M market capitalization and 41.0% operating margin.
OpEx & R&D Reinvestment 46.4% of Rev ($488M)
90D Engineering Disclosures 0 Published

Investor FAQ VTVT vs CRMD Key Questions & Quantitative Answers

As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over vTv Therapeutics Inc. (VTVT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VTVT carries a Unified Composite Score of 39.2/100 (SELL) at $17.62 (N/M Forward P/E, -29.8% operating margin), whereas CRMD carries 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin). Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (53.2/100 HOLD vs. VTVT 39.2/100 SELL) and 1.20β · 107% Vol risk profile, whereas VTVT leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VTVT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 19.7); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRMD leads the Growth & Scale pillar: VTVT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $37M TTM revenue (51.5% gross margin, -29.8% operating margin), compared with CRMD at -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.05B TTM revenue (87.4% gross margin, 41.0% operating margin). On trailing 12-month operating scale, VTVT generates $37M in USD-normalized revenue versus $1.05B for CRMD. In operating R&D and SG&A reinvestment, VTVT deploys 81.3% of Rev ($30M) (0 90-day corporate R&D disclosures) versus 46.4% of Rev ($488M) (0 disclosures) for CRMD.

CRMD screens cheaper on headline valuation multiples. VTVT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.1x EV/Revenue (-29.8% EBITDA margin), whereas CRMD trades at 49.0x Forward P/E, 2.4x Trailing P/E, 3.79x PEG, and N/M EV/Revenue (74.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTVT (-10.9% ROE) versus CRMD (15.3% ROE) capital efficiency.

In options market volatility and institutional positioning, VTVT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.48β · 53% Vol realized risk). By comparison, CRMD carries 56.3% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.69x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.20β · 107% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.